Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568533 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL24611526 | 0.81 | MAPT (0.56) | KDM4EALDH1A1MAPTGAAL3MBTL1 | |
| SCHEMBL27849216 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1MAPTGAALMNA | |
| Acetic Acid SCHEMBL367778 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL2980845 | 0.76 | BCAT2 (0.68) | KDM4EALDH1A1MAPTLMNAL3MBTL1 | |
| SCHEMBL9412965 | 0.75 | HPGD (0.49) | KDM4EALDH1A1MAPTGAAHPGD | |
| SCHEMBL14398905 | 0.75 | AXL (0.46) | KDM4EALDH1A1GAALMNAGLA | |
| SCHEMBL27204316 | 0.74 | BAZ2B (0.53) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL27494569 | 0.74 | ADORA2A (0.51) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL9412967 | 0.74 | HPGD (0.51) | KDM4EALDH1A1MAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | KDM4E 803/4885ALDH1A1 952/4885MAPT 4760/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | KDM4E 902/4885ALDH1A1 655/4885MAPT 4777/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | KDM4E 3140/4885ALDH1A1 881/4885MAPT 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.